Silicon Therapeutics (“SITX”) is a privately-held, physics-driven integrated drug discovery company in the preclinical IND stage targeting innate immunity to start, but with the capability to move into many other franchise opportunities. The Company’s initial pipeline is focused on modulation of the innate immune system to “light the spark” within immunologically cold tumors by using its physics-enabled drug discovery engine for the design of small molecule therapeutics and the lead program is in late stage preclinical studies. SITX’s discovery efforts as well as physics-based platform are all completely in-house, with a full wet lab as well as a team of over 25 experienced R&D professionals spanning biology, biochemistry, chemistry, biophysics (NMR + X-ray) & preclinical sciences. SITX’s engine leverages quantum mechanics and molecular dynamics, which are deployed on its own internal super computer composed of over 400 GPU’s and FPGA’s and allows SITX to accurately simulate the physical motion and properties of biological targets at an atomistic level resolution. The platform is completely proprietary to SITX and was built from the ground up with the purpose of addressing difficult targets and using simulations to break through bottlenecks that has plagued traditional drug discovery approaches on such targets. It is currently the ONLY company which owns the entire spectrum of physics-driven drug discovery from chip-to-clinic with a team of over 40 individuals in Boston.

The Company’s initial focus in on innate immunity and its pipeline is currently composed of one project entering into IND-enabling studies, another one entering hit-to-lead and two more ramping up. It’s unique advantage in designing small molecules using all atom simulations has allowed it to advance a systemically available small molecule STING agonist into a preclinical development. The program is ramping up for IND enabling studies entry to the clinic in 2020. This differentiated product can be administered systemically via an IV dose and has single agent effects in early mouse efficacy studies using PD1 resistant tumor models and is a “rule-of-5” compliant small molecule. Beyond this one program, the Company is also advancing an ADAR inhibitor which can be considered an innate immune check-point as well as a multitude of targets that explore Innate Immunity’s role in cancer biology.

SITX was founded out of the BIDMC in late 2016 and has raised ~50mm USD to date from leading investors including Sequoia & Chengwei Capital. The Company’s investors are long-term, premier brands that have the capability to hold businesses for decades and are believers in SITX’s mission and physics-driven approach.

Job Summary

Silicon Therapeutics is looking for an Associate, IT Support for its office at 451 D St for basic help desk support.

Job Responsibilities

Manage IT equipment in the office such as printers, Windows/Mac, laptops/desktops, VoIP Polycom phones, etc.

Set up monitors, laptops etc.  for new hires.

Debug/handle simple issues such as connecting multiple monitors, connecting company wireless network or using A/V equipment.

Troubleshoot biology/chemistry lab desktops issues such as network connectivity or common database issues.

Start and follow instructions from tech support calls on IT issues pertaining to Office365, Slack, Duo, Cisco VPN etc.

Required Skills & Qualifications

IT (Microsoft, Cisco etc.) Certification essential.

AA/BS (or equivalent) and <2 years of related experience required.

Comfortable in a help desk admin role.

Additional Desirable Qualifications

Experience with programming switches such as from Dell/Cisco.

Experience with Windows PowerShell, Active Directory setup

Experience with Cisco VPN devices.

Experience with basic Linux scripting.

Upload your CV/resume or any other relevant file. Max. file size: 256 MB.